![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
ENGINEERING SITE – SPECIFIC CONTROLLED – RELEASE DRUG DELIVERY SYSTEM BASED ON VARIOUS BIODEGRADABLE CHITOSAN – GUM CONJUGATED POLYMERS FOR THE TREATMENT OF COLORECTAL CANCER: A SCIENTIFIC NOTE
Partha Sarathi Roy*, Rahul Bhadoriya and Shubham Gupta
ABSTRACT One in 4 deaths in the United States is due to cancer. In 2015, about 589,430 Americans are expected to die of cancer, or about 1,620 people per day.[1(a, b)] Cancers are of many types like lung cancer, prostate cancer, colorectal cancer, breast cancer, etc. Among cancers, colorectal cancer (CRC) is the leading cause of cancer death worldwide, both in men and women, with 93,090 new cases and 49,700 deaths estimated to occur in 2015.[1(a, b)- 2] Within the family of non- steroidal anti-inflammatory medicinal drugs, celecoxib (CLX), a selective cyclooxygenase-2 inhibitor has been most frequently investigated for its anticancer activity against various in vitro and in vivo and has been shown to exert prominent effects in CRC therapy. It has also been reported that CLX was unable to prevent destruction due to its high biodegradability in the acidic media and thus rapidly dissolved in the gastric cavity. Hence, associations of serious side effects limit the usage of CLX in colon cancer treatment.[3,4] Therefore, the emphasis of the present paper is placed on finding alternative method for celecoxib administration, i.e., specific medicinal drug delivery systems to reduce the side effects and to increase anticancer activity. Keywords: Colorectal cancer, Celecoxib, Biodegradability, Medicinal drug delivery systems. [Download Article] [Download Certifiate] |